Clinical trial · Observational
The 1st Tumor CytokinoTherapy Database (TCTD-1)
Open Prospective Observational Cohort Study of the Effectiveness and Safety of Cytokinogenetic Therapy in Patients With Cancer Based on TCTD-1 Patient Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Predicting the response of patients diagnosed with cancer to cytokinotherapy is essential to guide anti-tumor therapy complex strategy and subsequent adjuvant approach. Cytokinotherapy is a cost-effective, well-known available method of therapy for the patients with tumors. The objective response possibly correlates to the tumor's size, aggressiveness, age, and other primary factors. Multifactor analysis requires a large amount of data. Therefore, the investigators created the first database aimed to collect data concerning the patients with cancer and the clinical outcomes of cytokinogenetic therapy. The acquired data must be processed to detect the key factors effecting the outcomes. Cytokinotherapy is a universal therapeutic approach, although we lack information that would help to personalize it and reduce the rate of progression. The main goal is to find the relationship between initial patients' characteristics and effectiveness of cytokinotherapy for early risks detection. The predictive models that could be elaborated from the TCTD-1 analysis will complement knowledge of cytokinotherapy rationale. Predicting survival or other significant clinical criteria using TCTD-1 analysis results would greatly benefit the cancer patients' management.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interferon gamma | Drug | — | UNRESOLVED |
| Tumor necrosis factor alpha | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- 10 years
- description
- Number of objective responses to therapy before progression or relapse.
Secondary outcomes (7)
- measure
- Changes in functional status since the start of cytokinegenetic therapy during treatment and observation.
- timeFrame
- 10 years
- description
- The Karnofsky index parameter will be evaluated.
- measure
- Overall survival of patients since the start of cytokinogenetic therapy.
- timeFrame
- 10 years
- description
- The time elapsed between the start of cytogenetic therapy and the death of the patient (for any reason, including those not related to oncology).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * adult patients aged 18 years or older with cancer who do not meet exclusion criteria, applied to the OncoCare308 Clinic Ltd. hospital for cytogenetic therapy, and are eligible to complete or have completed at least one course of cytogenetic therapy, as determined by the site. Exclusion Criteria: * Patients under 18 or over 95 years * Patients with hematologic cancer or thyroid tumors * Patients with contraindications for cytogenetic therapy * Patients who die before the start of therapy or before the first course completeness * Patients who do not sign the informed consent to be enrolled under the clinical observation in the hospital
References
Publications (0)
Data not yet available